Search research articles
Contact Us
Filters
Showing results (81-90 of 115) with videos related to
Page
of 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
February 18, 2021
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE
Andrew Dj Pearson, Steven G DuBois, Vickie Buenger, et al.
Expert Opinion on Drug Discovery
|
June 13, 2017
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project
Lucas Moreno, Hubert Caron, Birgit Geoerger, et al.
Nature Reviews. Clinical Oncology
|
February 9, 2019
Challenges to curing primary brain tumours
Kenneth Aldape, Kevin M Brindle, Louis Chesler, et al.
Nature Reviews. Clinical Oncology
|
June 1, 2019
Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'
Kenneth Aldape, Kevin M Brindle, Louis Chesler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours
Reda Stankunaite, Sally L George, Lewis Gallagher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastoma
Sveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 24, 2021
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium
Jack F Shern, Joanna Selfe, Elisa Izquierdo, et al.
Cancer Cell
|
December 24, 2014
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease
Rebecca M Hill, Sanne Kuijper, Janet C Lindsey, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
May 16, 2026
Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma
Lisa Mayr, Leah Mager, Lisa Gabler-Pamer, et al.
Molecular Cancer
|
June 10, 2022
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
Mareike Berlak, Elizabeth Tucker, Mathurin Dorel, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 115) with videos related to
Sort By:
Page
of 12
European Journal of Cancer (Oxford, England : 1990)
|
February 18, 2021
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE
Andrew Dj Pearson, Steven G DuBois, Vickie Buenger, et al.
Expert Opinion on Drug Discovery
|
June 13, 2017
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project
Lucas Moreno, Hubert Caron, Birgit Geoerger, et al.
Nature Reviews. Clinical Oncology
|
February 9, 2019
Challenges to curing primary brain tumours
Kenneth Aldape, Kevin M Brindle, Louis Chesler, et al.
Nature Reviews. Clinical Oncology
|
June 1, 2019
Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'
Kenneth Aldape, Kevin M Brindle, Louis Chesler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours
Reda Stankunaite, Sally L George, Lewis Gallagher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastoma
Sveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 24, 2021
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium
Jack F Shern, Joanna Selfe, Elisa Izquierdo, et al.
Cancer Cell
|
December 24, 2014
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease
Rebecca M Hill, Sanne Kuijper, Janet C Lindsey, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
May 16, 2026
Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma
Lisa Mayr, Leah Mager, Lisa Gabler-Pamer, et al.
Molecular Cancer
|
June 10, 2022
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
Mareike Berlak, Elizabeth Tucker, Mathurin Dorel, et al.
Page
of 12